


UpToDate recommendations\* for pneumococcal vaccination in immunocompetent† adults ≥ 65 years of age in the United States



PPSV23: 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23); PCV13: 13-valent pneumococcal conjugate vaccine (Pneumovax 13).

\* UpToDate's recommendations differ from those of the United States Advisory Committee on Immunization Practices (ACIP). Refer to the UpToDate topic on pneumococcal vaccination in adults for additional information.

† This algorithm applies only to immunocompetent patients ≥ 65 years of age who do not have anatomic or functional asplenia, a cochlear implant, or a cerebrospinal fluid leak. Refer to the relevant UpToDate topics for recommendations regarding other patient groups.

Δ Only a single dose of PCV13 is indicated during adulthood. The ACIP recommends PCV13 for all adults ≥ 65 years of age, but UpToDate recommends PCV13 only for adults ≥ 65 of age who have one of the conditions outlined above.

◊ The ACIP recommends a dose of PPSV23 at or after 65 years of age but does not recommend additional doses of PPSV23 every 10 years thereafter; by contrast, UpToDate recommends such revaccination.

References:

1. Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). *MMWR Morb Mortal Wkly Rep* 2010; 59:1102.
2. Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥ 65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* 2014; 63:822.

Graphic 107908 Version 3.0